Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alkermes plc before investing.

In this article, we go over a few key elements for understanding Alkermes plc’s stock price such as:

• Alkermes plc’s current stock price and volume
• Why Alkermes plc’s stock price changed recently
• Upgrades and downgrades for ALKS from analysts
• ALKS’s stock price momentum as measured by its relative strength

About Alkermes plc (ALKS)

Before we jump into Alkermes plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Want to learn more about Alkermes plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alkermes plc.

Alkermes plc’s Stock Price as of Market Close

As of April 24, 2026, 10:16 AM, CST, Alkermes plc’s stock price was $33.475.

Alkermes plc is down 1.28% from its previous closing price of $33.910.

During the last market session, Alkermes plc’s stock traded between $33.365 and $34.330. Currently, there are approximately 165.33 million shares outstanding for Alkermes plc.

Alkermes plc’s price-earnings (P/E) ratio is currently at 23.7, which is high compared to the Biotechnology industry median of 19.7. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Alkermes plc Stock Price History

Alkermes plc’s (ALKS) price is currently down 5.33% so far this month.

During the month of April, Alkermes plc’s stock price has reached a high of $36.480 and a low of $32.470.

Over the last year, Alkermes plc has hit prices as high as $36.480 and as low as $25.165. Year to date, Alkermes plc’s stock is up 19.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alkermes plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 23, 2026, there were 0 analysts who downgraded Alkermes plc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Alkermes plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alkermes plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Alkermes plc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alkermes plc (ALKS) by visiting AAII Stock Evaluator.

Relative Price Strength of Alkermes plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 23, 2026, Alkermes plc has a weighted four-quarter relative price strength of -1.03%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how Alkermes plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alkermes plc Stock Price: Bottom Line

As of April 24, 2026, Alkermes plc’s stock price is $33.475, which is down 1.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alkermes plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.